{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:25:59Z","timestamp":1787199959093,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have become the standard therapy for unresectable hepatocellular carcinoma (HCC). However, reliable prognostic biomarkers for treatment response remain warranted. This study assessed the prognostic value of early C-reactive protein (CRP) kinetics as an on-treatment biomarker in patients with hepatocellular carcinoma receiving ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, 289 patients with HCC treated with ICIs between 2019 and 2023 were analyzed. Patients were stratified using two established CRP kinetic models. The Fukuda model classified patients as flare responders, responders, or non-responders based on early CRP kinetics after treatment initiation. The Ishihara model categorized patients as \u201cnormal\u201d, \u201cnormalized\u201d, or \u201cnon-normalized\u201d according to baseline and on-treatment CRP levels. Both models were additionally evaluated at eight weeks for earlier risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>According to the Fukuda model, flare responders demonstrated significantly prolonged median overall survival (34.5 vs 12.7 months), progression-free survival (12.42 vs 5.32 months), and higher objective response rates (53.7% vs 25.2%) compared with non-responders. In the Ishihara model, the normalized and normal groups showed significantly improved outcomes with median overall survival of 28.35 and 25.1 months, progression-free survival of 12.48 and 9.89 months, and objective response rates of 54.2% and 43.4%, respectively, compared with the non-normalized group (7.46 months; 3.35 months; 18.8%). The adapted 8-week Ishihara model enabled earlier risk stratification prior to first radiologic staging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early C-reactive protein kinetics provide robust prognostic information in patients with HCC treated with ICIs. Both CRP-based models identify subgroups with significantly improved outcomes, with the Ishihara model enabling earlier identification of patients at high risk of treatment failure and thereby supporting earlier risk stratification during immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1889205","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:45Z","timestamp":1787199345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions"],"prefix":"10.3389","volume":"16","author":[{"given":"Joshua","family":"Leutiger","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Cologne, Faculty of Medicine, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Bathon","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00f6hring","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University Hospital of Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Ole","family":"Hubert","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Hospital, Ludwig Maximilian University Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Leyh","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital D\u00fcsseldorf, Medical Faculty of Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Emilia","family":"Schlaak","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Medical Center University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Mitzlaff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, University Hospital Schleswig-Holstein","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Kr\u00e4mer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Cologne, Faculty of Medicine, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Neumann-Haefelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Cologne, Faculty of Medicine, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Zimpel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, University Hospital Schleswig-Holstein","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Bengsch","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Medical Center University of Freiburg","place":["Freiburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[{"name":"Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital D\u00fcsseldorf, Medical Faculty of Heinrich Heine University D\u00fcsseldorf","place":["D\u00fcsseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Ben Khaled","sequence":"additional","affiliation":[{"name":"Department of Medicine II, University Hospital, Ludwig Maximilian University Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cennet","family":"Sahin","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen (RWTH) Aachen","place":["Aachen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Luise","family":"Berres","sequence":"additional","affiliation":[{"name":"Medical Department III, University Hospital Rheinisch-Westf\u00e4lische Technische Hochschule Aachen (RWTH) Aachen","place":["Aachen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gonzalez-Carmona","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, University Hospital of Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lena","family":"Saborowski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz","place":["Mainz, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Waldschmidt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Cologne, Faculty of Medicine, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Allo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Cologne, Faculty of Medicine, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000520095","article-title":"Advances in pharmacotherapy of hepatocellular carcinoma: a state-of-the-art review","volume":"40","author":"Reiter","year":"2022","journal-title":"Dig Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"113248","DOI":"10.1055\/s-0042-1760037","article-title":"Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study","volume":"192","author":"Ben Khaled","year":"2023","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101513","article-title":"Early mortality in atezolizumab\/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity","volume":"7","author":"Piseddu","year":"2025","journal-title":"JHEP Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.003","article-title":"Combination immunotherapy for hepatocellular carcinoma","volume":"79","author":"Rimassa","year":"2023","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000533991","article-title":"Safety and efficacy of atezolizumab\/bevacizumab in patients with hepatocellular carcinoma and impaired liver function: a systematic review and meta-analysis","volume":"13","author":"Pasta","year":"2024","journal-title":"Liver Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.3390\/ijms24043441","article-title":"Tumor mutational burden for predicting prognosis and therapy outcome of hepatocellular carcinoma","volume":"24","author":"Gabbia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.69645\/oxql1823","article-title":"Biomarkers for immunotherapy of hepatocellular carcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3390\/diagnostics14182054","article-title":"Biomarkers for immunotherapy efficacy in advanced hepatocellular carcinoma: a comprehensive review","volume":"14","author":"Taherifard","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.3390\/cancers12123830","article-title":"Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 inhibition in hepatocellular carcinoma","volume":"12","author":"Spahn","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0168","article-title":"Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2023","journal-title":"Immunotherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1291840","article-title":"Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0048-z","article-title":"Role of nonresolving inflammation in hepatocellular carcinoma development and progression","volume":"2","author":"Yu","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5495","article-title":"New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study","volume":"12","author":"Tada","year":"2023","journal-title":"Cancer Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101295","article-title":"Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab","volume":"7","author":"Gairing","year":"2025","journal-title":"JHEP Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001564","article-title":"Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab","volume":"9","author":"Fukuda","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejca.2022.02.022","article-title":"C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma","volume":"167","author":"Klumper","year":"2022","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004024","article-title":"C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer","volume":"10","author":"Klumper","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-023-00005-x","article-title":"C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer","volume":"1","author":"Nose","year":"2023","journal-title":"BJC Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s432054","article-title":"Early C-reactive protein kinetics predict response to immune checkpoint blockade in unresectable hepatocellular carcinoma","volume":"10","author":"Qin","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.12.008","article-title":"Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma","volume":"38","author":"Ishihara","year":"2020","journal-title":"Urol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1695861","article-title":"The prognostic and predictive value of AFP in immune checkpoint inhibitor-treated hepatocellular carcinoma: a systematic review and meta-analysis","volume":"16","author":"Tian","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211399","article-title":"Significant association between high neutrophil-lymphocyte ratio and poor prognosis in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000639","article-title":"Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma","volume":"94","author":"Gao","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1471","article-title":"Early CRP kinetics to predict long-term efficacy of first-line immune-checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real-world experience applying different CRP kinetics definitions","volume":"12","author":"Hoeh","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2019.10.18","article-title":"Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B\/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study","volume":"8","author":"Huang","year":"2019","journal-title":"Transl Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2007.01550.x","article-title":"Serum C-reactive protein levels predict survival in hepatocellular carcinoma","volume":"27","author":"Nagaoka","year":"2007","journal-title":"Liver Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1657733","article-title":"C-reactive protein flare: a promising prognostic predictor for patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and immune checkpoint inhibitors","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.01.007","article-title":"Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma","volume":"80","author":"Chan","year":"2024","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"101630","DOI":"10.1016\/j.jhepr.2025.101630","article-title":"Navigating second-line therapy after immunotherapy in advanced HCC","volume":"8","author":"Vogel","year":"","journal-title":"JHEP Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115163","article-title":"The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression","volume":"215","author":"Saal","year":"2025","journal-title":"Eur J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26057","article-title":"Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma","volume":"57","author":"Sieghart","year":"2013","journal-title":"Hepatology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1329634","article-title":"Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgv123","article-title":"Immunosuppression associated with chronic inflammation in the tumor microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \"cancer immunogram","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.07.027","article-title":"Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma","volume":"16","author":"Nakayama","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","article-title":"Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer","volume":"13","author":"Sui","year":"2022","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12032-019-1255-3","article-title":"Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer","volume":"36","author":"Ozawa","year":"2019","journal-title":"Med Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:46Z","timestamp":1787199346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":53,"alternative-id":["10.3389\/fonc.2026.1889205"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1889205","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1889205"}}